Summary
14.76
1.09
(7.97%)
06/12/2026
Avalo Therapeutics, Inc. (AVTX)Key Facts
Performance
Historical returns1D
7.97%
1W
15.86%
1M
-25.98%
3M
-11.67%
6M
-20.65%
1Y
202.46%
5Y
-99.85%
Snapshot
Key statisticsClose
14.76
Change
1.09
Change %
7.97%
Open
14.09
Day Range
13.96 – 14.82
Volume
1,120,669
Avg Vol (20d)
1,444,115
Rel Vol
0.78x
52W Range
4.46 - 24.27
vs 52W High
-39.18%
vs 52W Low
230.94%
Gap
0.20
Market Cap
USD 192.68M
Beta
0.96
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
Financial SnapshotFY 2025
Full financialsRevenue
USD 59.00K
-86.6% YoY
Net Income
-USD 78.26M
+122.8% YoY
EPS
-5.84
+35.2% YoY
Gross Margin
100.0%
Operating Margin
-123,601.7%
Net Margin
-132,642.4%
EBITDA
-USD 72.58M
Free Cash Flow
-USD 51.46M
-87,216.9% margin
ROE
-94.2%
ROA
-67.2%
Debt / Equity
0.03x
net debt -USD 13.43M
Cash & Equiv.
USD 15.86M
Fundamental Ratings
MainC
RecommendedSell
DCFNeutral
ROEStrong Sell
ROAStrong Sell
Debt/EquityNeutral
P/EStrong Sell
P/BSell
Latest Earnings
- AVTX reported last earnings on 2026-05-13.
- EPS of $-0.98 vs $-1 estimated — surprise $0.02.
- Revenue of $0M vs $0M estimated — surprise $0M.
News
All newsAvalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company granted an inducement award consisting of an...
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and first quarter 2026...
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced the pricing of its underwritten public offering...
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced that it has commenced an underwritten public...
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced positive topline results from its Phase 2 LOTUS trial...
Avalo Therapeutics Purchases Optional Milestone Buyout
WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced that it has entered into a Milestone Buyout...
Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $42.25
Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have given a buy recommendation...
Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More
Pre-Market Stock Futures: Futures are trading mixed as we get ready to kick off the first-quarter earnings season next week, and, as usual, the big money-center banks and brokerage firms will headline the first results. All of the major U.S. indices saw wild swings on Thursday, and after opening...
Avalo Therapeutics (NASDAQ:AVTX) Insider Sells $10,864.00 in Stock
Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) insider Mittie Doyle sold 679 shares of the firm's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $16.00, for a total value of $10,864.00. Following the completion of the transaction, the insider...
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Avalo Therapeutics (AVTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and year-end financial...
Ally Bridge Group NY LLC Purchases New Position in Avalo Therapeutics, Inc. $AVTX
Ally Bridge Group NY LLC acquired a new position in Avalo Therapeutics, Inc. (NASDAQ: AVTX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 178,100 shares of the company's stock, valued at approximately $2,264,000. Avalo...
Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference
Avalo Therapeutics (NASDAQ: AVTX) CEO Garry Neil said the company expects to report top-line data in the second quarter from its completed Phase 2b LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS), outlining what he described as operational execution milestones in 2025 and the rationale for...
Silence Therapeutics (NASDAQ:SLN) versus Avalo Therapeutics (NASDAQ:AVTX) Head-To-Head Comparison
Avalo Therapeutics (NASDAQ: AVTX - Get Free Report) and Silence Therapeutics (NASDAQ: SLN - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk,...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor...
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
WAYNE, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to two new employees....
Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Price Target at $34.88
Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have issued a...
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case
Avalo Therapeutics Inc.'s (NASDAQ: AVTX) completed enrollment of the Phase 2 LOTUS trial of AVTX-009, the company's lead drug candidate.